People: Medivation Inc (MDVN.O)

MDVN.O on Nasdaq

76.43USD
2:37pm EDT
Price Change (% chg)

$0.12 (+0.15%)
Prev Close
$76.31
Open
$77.50
Day's High
$77.61
Day's Low
$75.72
Volume
376,703
Avg. Vol
941,100
52-wk High
$88.20
52-wk Low
$48.15

Search Stocks

Summary

Name Age Since Current Position

Kim Blickenstaff

61 2007 Independent Chairman of the Board

David Hung

56 2004 President, Chief Executive Officer, Director

Rick Bierly

58 2014 Chief Financial Officer, Principal Financial and Accounting Officer

Stephen Kelsey

53 2013 Senior Vice President - New Projects

Jennifer Rhodes

44 2013 Chief Compliance Officer, General Counsel, Corporate Secretary

Dawn Svoronos

60 2014 Interim Chief Commercial Officer, Director

Lynn Seely

55 2005 Chief Medical Officer

C. Patrick Machado

50 2014 Director

Daniel Adams

73 2005 Independent Director

Kathryn Falberg

53 2013 Independent Director

W. Anthony Vernon

58 2006 Independent Director

Wendy Yarno

59 2013 Independent Director

Biographies

Name Description

Kim Blickenstaff

Mr. Kim D. Blickenstaff is an Independent Chairman of the Board of Medivation, Inc., since 2005. He has served as as the Chairman of the Board since 2007. Mr. Blickenstaff is a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. Mr. Blickenstaff has been President and Chief Executive Officer of Tandem Diabetes Care, a privately held company focusing on improved insulin infusion therapy, since September 2007. From 1988 until August 2007, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products. Mr. Blickenstaff was a director of SenoRx, Inc., a public company that is focused on developing improved breast cancer biopsy and treatment devices from 2002 to 2010, and was a member of its compensation committee. Mr. Blickenstaff was formerly a certified public accountant and has more than 10 years of experience overseeing the preparation of financial statements. Mr. Blickenstaff received a B.A. from Loyola University, Chicago and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

David Hung

Dr. David T. Hung, M.D. has been President, Chief Executive Officer, Director of Medivation, Inc. He is a member of the Board, since December 2004. Previously, Dr. Hung served as the President and Chief Executive Officer, and member of the board of directors, of Medivation Neurology, Inc. from its inception in September 2003 through December 2004, when it became the wholly owned subsidiary by merger. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999) and as President and Chief Executive Officer (1999-2001). Dr. Hung served as a consultant to Cytyc Corporation from 2001 until 2002 to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Hung is a director and member of the compensation committee of Opexa. Dr. Hung received an M.D. from the University of California, San Francisco, School of Medicine, and an A.B. in Biology from Harvard College. Dr. Hung is a co-founder of Medivation, has served as the President and Chief Executive Officer since inception, and is responsible for the overall corporate strategy and selection of the product development candidates.

Rick Bierly

Mr. Rick Bierly is Chief Financial Officer, Principal Financial and Accounting Officer of the Company. He brings to Medivation over 30 years experience in finance roles at Glaxo-SmithKline, Aventis, Centocor and Johnson & Johnson. Mr. Bierly served as an executive director in Ernst & Young’s (EY) Financial Accounting Advisory Services practice for life sciences and other clients from September 2013 to present, where he provided advisory services in connection with Finance function transformations. From 1999 to 2012, he served in several leadership roles at Johnson & Johnson, including vice president, Skillman NJ Shared Financial Services Center, where he was responsible for a shared services center providing financial accounting services to Johnson and Johnson’s US-based operating companies. Mr. Bierly also served as vice president and chief financial officer of Centocor and Ortho Biotech, and prior to that served as executive director, finance, following the acquisition of the Centocor biotechnology business by Johnson and Johnson. From 1997 to 1999 he was at Centocor Diagnostics as vice president and chief financial officer and Centocor as executive director, finance. From 1995 to 1997 he served as vice president and treasurer of a Aventis-Hoechst start-up joint venture in the blood plasma business. He also worked in senior financial roles at Aventis (1991 to 1995) and SmithKline Beecham (1981 to 1991). Mr. Bierly began his career in public accounting at EY. He holds a Bachelor of Business Administration degree from Pennsylvania State University and is a CPA in PA and NJ.

Stephen Kelsey

Dr. Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., is Senior Vice President - New Projects of Medivation, Inc. He joins Medivation from Geron Corporation where he served as the executive vice president, research & development and chief medical officer. From 2009 to 2011 he served as executive vice president and chief medical officer, oncology at Geron. From 2002 to 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as vice president, clinical hematology/oncology, where he was responsible for the oncology late stage development portfolio including Rituxan(R), Herceptin(R), Tarceva(R), Perjeta(R), Kadcyla(TM), Erivedge(R) and five additional development products in solid tumors and hematologic malignancies. From 2000 to 2002, Dr. Kelsey was the director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.), where he was responsible for Sutent(R), and director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the University of Birmingham in the United Kingdom.

Jennifer Rhodes

Jennifer J. Rhodes is Chief Compliance Officer, General Counsel and Corporate Secretary of Medivation Inc., since March 26, 2013. Ms. Rhodes joined Medivation in June 2012 as our General Counsel, and was appointed Chief Compliance Officer in July 2012 and Corporate Secretary in April 2013. Between May 2006 and June 2012, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc. where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group, and served as a legal product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer Inc., Ms. Rhodes was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP from October 2000 to April 2006. Between September 1998 and August 2000, Ms. Rhodes served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.

Dawn Svoronos

Ms. Dawn Svoronos is Interim Chief Commercial Officer, Director of Medivation, Inc., since July 10, 2014. Ms. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. Inc, where she oversaw commercial operations in approximately 30 EU and EU accession countries. Ms. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the Company's search for a permanent chief commercial officer. Ms. Svoronos, who was elected to Medivation's Board of Directors in April 2013, has more than 30 years of pharmaceutical industry experience spanning the U.S., Europe, Asia and Canada. In March 2011, Ms. Svoronos retired from Merck & Co., Inc, one of the world's leading healthcare companies, where she worked in the commercial side of the organization for 23 years. Ms. Svoronos is a former President of Europe and Canada for Merck. Before moving to Europe, Ms. Svoronos was President of Merck in Canada and prior to that, she was Vice President of Merck for Asia Pacific where she focused on advancing the commercial interests of Merck in Japan, China, and several other countries in Southeast Asia.

Lynn Seely

Dr. Lynn Seely, M.D. is the Chief Medical Officer of Medivation, Inc. From September 2002 to March 2005, Dr. Seely served as Vice President of Clinical Development at Anesiva, Inc., formerly Corgentech Inc., a biomedical company. From 1996 through 2000, Dr. Seely served as an Associate Director of Clinical Development at Chiron Corporation, a biotechnology company. Dr. Seely served as Vice President of Clinical Development at ProDuct Health, Inc., a privately held medical device company, from 2000 to 2001. Dr. Seely subsequently served as Vice President of Clinical Development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, a medical device company, from 2001 to 2002, where she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine and completed her residency in internal medicine at Yale-New Haven Hospital.

C. Patrick Machado

Mr. C. Patrick Machado, J.D., is Director of Medivation, Inc. Mr. Machado previously served as Medivation's chief business officer since December 2009 and its chief financial officer since December 2004. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately held medical device company, as vice president, chief financial officer and general counsel (1998-2000) and as senior vice president and chief financial officer ( 2000-2001). From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation's acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.

Daniel Adams

Mr. Daniel D. Adams is Independent Director of Medivation, Inc., since 2005. Mr. Adams has been the Executive Chairman of Protein Sciences Corporation, a biopharmaceutical company, since 2010 and Chairman of its board of directors since April 2009. He previously served as President and Chief Executive Officer of Protein Sciences Corporation from July 1996 until he became Executive Chairman in 2010. Mr. Adams also was a co-founder and the first Chief Executive Officer of Biogen, and the founder and Chief Executive Officer of Advanced Genetic Sciences, Inc., Plant Genetic Systems and Allerx, Inc. Mr. Adams holds a B.A. in Chemistry from Cornell University and a J.D. magna cum laude from New York University School of Law.

Kathryn Falberg

Kathryn E. Falberg is an Independent Director of Medivation Inc., since January 31, 2013. Ms. Falberg is currently the Chair of our Audit Committee and a member of our Compensation Committee. Ms. Falberg currently serves as the Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc. She also served as its Senior Vice President and Chief Financial Officer from 2009 to 2012. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Ms. Falberg worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies, and from February 2009 to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant. Ms. Falberg currently serves on the board of directors and is the chair of the Audit Committee of Halozyme Therapeutics, Inc., a biopharmaceutical company, and previously served on the board of directors of QLT Inc.

W. Anthony Vernon

Mr. W. Anthony Vernon is an Independent Director of Medivation, Inc. He has served at Kraft Foods, Inc., a publicly held food company, as Executive Vice President and President, Kraft Foods of North America since 2009. From 2006 to 2009, Mr. Vernon was the Healthcare Industry Partner at Ripplewood Holdings, Inc., a private equity firm. Mr. Vernon had previously led a number of Johnson & Johnson’s franchises during a 24-year career at Johnson & Johnson, a public company engaged in the research and development, manufacture and sale of products in the health care field. From 2004 until 2005, Mr. Vernon was employed as Company Group Chairman of Depuy Inc., an orthopedics company which is a subsidiary of Johnson & Johnson. From 2001 until 2004, Mr. Vernon served as President and Chief Executive Officer of Centocor, Inc., a biomedicines company which is a division of Johnson & Johnson. He has also served as President of McNeil Consumer Products and Nutritionals, Worldwide President of The Johnson & Johnson-Merck Joint Venture and as a member of Johnson & Johnson’s Group Operating Committees for Consumer Healthcare and Nutritionals, Biopharmaceuticals, and Medical Devices and Diagnostics. He is also a director of several consumer, biotech and medical device companies, including NovoCure Ltd. and Zeo, Inc., and was formerly a director of Uluru Inc., a public specialty pharmaceutical company, from August 2007 to December 2009. Mr. Vernon also serves as a director of the Philadelphia Youth Organization, a non-profit foundation. Mr. Vernon received a B.A. from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management.

Wendy Yarno

Ms. Wendy L. Yarno has been appointed as an Independent Director of Medivation, Inc., effective April 26, 2013. since April 2013. Ms. Yarno retired in September 2008 from Merck & Co., Inc. following a 26-year career there in commercial and human resource positions of increasing seniority, most recently Chief Marketing Officer before she retired. In that role, Ms. Yarno led a global organization charged with all aspects of supporting pre- and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Prior to this role, she served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, where she had P&L responsibility for Merck’s largest therapeutic area, and as Senior Vice President, Human Resources. After retiring from Merck, Ms. Yarno worked part-time as the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, from September 2010 through September 2011. Since September 2011, Ms. Yarno has been an independent consultant in the life sciences industry. Ms. Yarno has served as a director of St. Jude Medical, Inc., a Fortune 500 medical device company, since 2002 and Aratana Therapeutics, a biopharmaceutical company developing medicines for pets, since October 2013

Basic Compensation

Name Fiscal Year Total

Kim Blickenstaff

--

David Hung

2,300,540

Rick Bierly

--

Stephen Kelsey

3,547,360

Jennifer Rhodes

1,581,770

Dawn Svoronos

--

Lynn Seely

1,083,020

C. Patrick Machado

1,082,490

Daniel Adams

--

Kathryn Falberg

--

W. Anthony Vernon

--

Wendy Yarno

--
As Of 30 Dec 2013

Options Compensation

Search Stocks